Vendor, Fort Collins, CO
Solaris Vaccines, Inc.
UEI G1P5NEDCERA9, CAGE 97FY7
2 awards and $1,548,155 obligated between June 12, 2024 and June 4, 2026, 100% under full and open competition, against 3.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $1,548,155 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HT942525C0028Definitive Contract, July 1, 2025, Full and Open Competition After Exclusion of Sources, 3 offers | Army Med Res Acq ActivityDefense Health Agency | DHA Phase II SBIR Contract for Vacciraptor: High-Throughput, Continuous Flow-Through System for Psoralen-Uva InactivationNAICS 541715, PSC AN12 | $1,298,431 |
| HT942524P0078Purchase Order, June 12, 2024, Full and Open Competition After Exclusion of Sources, 3 offers | Army Med Res Acq ActivityDefense Health Agency | DHA SBIR Phase I Vacciraptor: High-Throughput, Continuous Flow-Through Device for Psoralen-Uva Inactivation of Dengue VirusNAICS 541715, PSC AN11 | $249,723 |
- Places of performance
- Colorado
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 4 across 2 awards